<DOC>
	<DOCNO>NCT01821911</DOCNO>
	<brief_summary>The objective study achieve post-marketing safety immunogenicity research Speeda® rabies vaccine human use Chengda Bio</brief_summary>
	<brief_title>The Post-Marketing Safety Immunogenicity Research Speeda® Rabies Vaccine Human Use</brief_title>
	<detailed_description>The aim research compare two immune procedure . The investigator plan enroll 10500 participant sign informed consent separately inject Zagreb Essen procedure .</detailed_description>
	<mesh_term>Rabies</mesh_term>
	<criteria>Parent/legal acceptable representative child adult participant willing able understand protocol requirement provide informed consent sign Participant consider good health include body mental status basis report medical history limited physical examination live local ≥ 12 month Participant body temperature ≤ 37.0℃ Participant without preventive inoculation rabies vaccine ( limited immunogenicity subgroup ) Threelevel exposure Known allergy constituent vaccine Reported history allergy , convulsion , epilepsy , mental illness brain disease clear serious systemic reaction Known bleeding disorder suspect impairment immunologic function , receipt immunosuppressive therapy immunoglobulin since birth Participation interventional clinical trial An acute illness without fever ( temperature ＞ 37.0℃ ) late week precede enrollment trial Inoculated vaccine , immunoglobulin investigational drug within 4 week prior participation study Reported clearly infection upper respiratory tract 6 month Clinical Manifestation Metabolic , blood system , lung , heart , gastrointestinal tract , nervous system , kidney , urinary system , endocrine , liver disease malignant tumor Any condition , opinion investigator , would pose health risk subject interfere vaccine</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>